https://biotechmorning.com/news/flap-inhibitor-asthma-failure-astrazeneca Biotech Morning en 2026-04-29T14:13:02.522Z The Asthma Drug Class That Just Can't Catch a Break https://biotechmorning.com/news/teva-emalex-tourette-syndrome-deal Biotech Morning en 2026-04-29T14:12:21.980Z Teva Just Dropped $700M on a Drug for a Disease With Limited Treatment Options https://biotechmorning.com/news/fda-real-time-clinical-trial-review Biotech Morning en 2026-04-29T14:11:38.909Z The FDA Wants to Watch Your Clinical Trial Live https://biotechmorning.com/news/gsk-oncology-gamble-future Biotech Morning en 2026-04-29T14:10:59.733Z GSK's Oncology Gamble Could Rewrite Its Entire Future https://biotechmorning.com/news/coultreon-galapagos-drug-125m-series-a Biotech Morning en 2026-04-29T14:10:23.844Z Galapagos Ditched This Drug. Now It Just Raised $125 Million. https://biotechmorning.com/news/incyte-opzelura-vitiligo-rinvoq-competition Biotech Morning en 2026-04-29T14:09:42.929Z Incyte's Skin Cream Just Won Big. So Why Is Wall Street Nervous? https://biotechmorning.com/news/erasca-home-run-stock-drops Biotech Morning en 2026-04-29T14:08:52.547Z Erasca Hit a Home Run. The Stock Fell 47%. https://biotechmorning.com/news/astrazeneca-fda-concerns-camizestrant-truqap Biotech Morning en 2026-04-29T14:08:05.823Z AstraZeneca's Two Biggest Cancer Bets Just Hit a Wall https://biotechmorning.com/news/compass-therapeutics-trial-crossover-problem Biotech Morning en 2026-04-28T14:13:28.669Z The Trial That Worked Too Well for Its Own Good https://biotechmorning.com/news/oruka-psoriasis-data-vs-skyrizi Biotech Morning en 2026-04-28T14:12:38.952Z The Tiny Biotech That Just Embarrassed a Billion-Dollar Drug https://biotechmorning.com/news/sun-pharma-organon-acquisition-12-billion Biotech Morning en 2026-04-28T14:11:51.311Z India's Generics King Just Bet $12 Billion It Can Play in the Big Leagues https://biotechmorning.com/news/survodutide-obesity-drug-wasnt-supposed-to-work Biotech Morning en 2026-04-28T14:11:08.851Z The Obesity Drug That Wasn't Supposed to Work https://biotechmorning.com/news/coultreon-biopharma-125m-galapagos-rescued-assets Biotech Morning en 2026-04-28T14:10:23.576Z Biotech's Hottest New Strategy: Raiding Big Pharma's Junk Drawer https://biotechmorning.com/news/astellas-gene-therapy-plan-b Biotech Morning en 2026-04-28T14:09:40.279Z Astellas Spent $3 Billion on a Gene Therapy. Now It's Trying Plan B. https://biotechmorning.com/news/two-biotechs-ipo-same-day-biotech-window Biotech Morning en 2026-04-28T14:09:05.056Z Two Biotechs Just Rang the IPO Bell on the Same Day https://biotechmorning.com/news/janux-kills-solid-tumor-t-cell-engager Biotech Morning en 2026-04-28T14:08:21.642Z Janux Just Killed Its Biggest Solid Tumor Bet. The Reason Should Worry Everyone. https://biotechmorning.com/news/novartis-in-vivo-car-t-evaluation Biotech Morning en 2026-04-28T14:07:35.789Z The Company That Invented CAR-T Is Watching From the Sidelines https://biotechmorning.com/news/lilly-profluent-ai-gene-editing-deal Biotech Morning en 2026-04-28T14:06:52.641Z Eli Lilly Just Paid $2.25 Billion for a Gene Editor That Doesn't Exist in Nature